TrialCancer immunology, immunotherapy : CII2022

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.

David M Loeb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.